Oncology revenue is expected to grow approximately 15% year over year in 2025. Excluding non-recurring, out of period revenue recorded in 2024, ...
Stifel raised the firm’s price target on Guardant Health (GH) to $53 from $45 and keeps a Buy rating on the shares. Q4 revenue beat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback